Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Blood Rev ; 32(2): 89-95, 2018 03.
Article in English | MEDLINE | ID: mdl-29033137

ABSTRACT

Acute promyelocytic leukemia (APL) is a hyper-acute illness and presents with profound cytopenias in most patients and disseminated intravascular coagulation (DIC). Excellent treatment options are now available with drugs such as all-trans retinoic acid (ATRA), arsenic trioxide (ATO), anthracyclines and cytarabine. The outcome in APL has improved tremendously in the last 50years due to better understanding of the disease, development of effective targeted agents and improvement in supportive care. Carefully selected groups of patients treated in large multi-center trials on a protocol and in experienced centers have shown survival rates in excess of 85%. However population data and other studies show that approximately 30% of patients die during induction. This is an Institutional, national and global problem and remains a pressing and frustrating challenge in APL. While most APL experts are aware of the high rate of early deaths (ED), such awareness is not typically present among general hematologists and oncologists. Our area of focus over the last 7years has been the reduction of ED in both academic and community centers; as a result we have acquired substantial experience in APL induction. Two centers have implemented population-wide prospective trials; Brazil and Georgia/South Carolina, USA with improvement in the ED rate. Both centers used standardized guidelines along with consultative support and sharing of expertise which proved effective and helped to decrease ED. Induction mortality in APL is 30% or greater. We believe ED is largely preventable and population-wide survival can be improved. An effective strategy is to utilize a set of simplified treatment guidelines coupled with support from a group of experts during induction. Treating oncologists in both academic and community hospitals should receive aggressive education about ED and be encouraged to seek advice from a core group of established APL experts. This model could be implemented nationally to improve population-wide survival in this most curable leukemia.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Leukemia, Promyelocytic, Acute/mortality , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cause of Death , Health Care Surveys , Hemorrhage/etiology , Hemorrhage/mortality , Humans , Induction Chemotherapy/adverse effects , Leukemia, Promyelocytic, Acute/complications , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/epidemiology , Mortality , Risk Factors , Treatment Outcome
2.
Int J Lab Hematol ; 37(4): 515-20, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25639817

ABSTRACT

INTRODUCTION: Acute Promyelocytic Leukemia (APL) is a curable malignancy with studies showing above 90% survival. However, population-based studies looking at survival suggest that approximately 30% of patients with APL die during induction. Early demonstration of t(15;17) will lead to accurate decision making regarding treatment. The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h). METHODS: Twenty patients (15 APL cases and five non-APL cases) were selected for validating various hybridization times for the FISH probe. Expected normal signal pattern was two red and two green signals (2R2G), and the most common expected abnormal signal pattern was two fusion (yellow) signals, one red and one green (2F1R1G) and/or one fusion, one red and one green (1F1R1G). RESULTS: The specificity of the probe ranged from 84% at 2 h, 86% at 4 h, 84% at 6 h, and 87% for overnight hybridization. The sensitivity increased from 79% at 2 h, 80% at 4 h, 81% at 6 h to 87% for overnight hybridization. CONCLUSION: Based on the validation studies, we recommend reading of FISH results at the 4-h incubation mark for a preliminary diagnosis and confirmation with overnight hybridization.


Subject(s)
Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/genetics , Receptors, Retinoic Acid/genetics , Translocation, Genetic , Bone Marrow/metabolism , Bone Marrow/pathology , Case-Control Studies , Chromosomes, Human, Pair 15 , Chromosomes, Human, Pair 17 , Clinical Decision-Making , Early Diagnosis , Gene Expression , Humans , In Situ Hybridization, Fluorescence , Leukemia, Promyelocytic, Acute/pathology , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Lymph Nodes/metabolism , Lymph Nodes/pathology , Retinoic Acid Receptor alpha , Sensitivity and Specificity , Time Factors
4.
Clin Exp Dermatol ; 39(4): 448-53, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24825135

ABSTRACT

BACKGROUND: Perioral dermatitis (POD) is a common skin disease, and extending the range of treatments available for this condition is important. AIM: To evaluate the safety, efficacy and tolerability of praziquantel 3% ointment as monotherapy. METHODS: This was a single-centre, randomized, single-blind, vehicle-controlled pilot study in adult patients (n = 46) with 4 weeks of treatment and 4 weeks of follow-up. Efficacy was assessed clinically using the Investigator's Global Assessment (IGA) and the Perioral Dermatitis Severity Index (PODSI). Quality of life (QOL) was determined by the Dermatology Quality of Life Index (DLQI). RESULTS: PODSI was significantly lower in the praziquantel group than in the placebo (vehicle) group, both during treatment and period. Mean IGA score showed a statistically significant therapeutic advantage of praziquantel over placebo at week 4 (P < 0.001). The praziquantel group experienced a greater improvement in mean DLQI. No serious treatment-related adverse events occurred in either group. CONCLUSIONS: Praziquantel ointment 3% effectively improves POD symptoms and QOL.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Dermatitis, Perioral/drug therapy , Praziquantel/administration & dosage , Administration, Topical , Adolescent , Adult , Anti-Inflammatory Agents/adverse effects , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Praziquantel/adverse effects , Quality of Life , Single-Blind Method , Young Adult
5.
Bone Marrow Transplant ; 48(10): 1279-84, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23584435

ABSTRACT

Studies comparing the efficacy and cost of stem cell mobilization with intermediate-dose CY (ID-CY) and G-CSF against plerixafor and G-CSF, specifically in multiple myeloma (MM) patients treated in the novel therapy era, are not available. Eighty-eight consecutive patients undergoing mobilization with ID-CY (3-4 g/m(2)) and G-CSF (n=55) were compared with patients receiving plerixafor and G-CSF (n=33). Compared with plerixafor, ID-CY use was associated with higher median peak peripheral blood CD34+ cell count (68 vs 160 cells/µL, P<0.001), and CD34+ cell yield on day 1 of collection (6.9 × 10(6) vs 11.7 × 10(6) cells/kg, P<0.001). Total CD34+ cell yield was significantly higher in the ID-CY patients (median collection 16.6 × 10(6) vs 11.6 × 10(6) cells/kg; P<0.001). ID-CY use was associated with significantly more frequent episodes of febrile neutropenia (16.3% vs 0%; P=0.02), intravenous antibiotic use (16.3% vs 3%; P=0.03) and hospitalizations (P=0.02). The average total cost of mobilization in the plerixafor group was significantly higher compared with the ID-CY group ($28 980 vs $22 504.8; P=0.001). Our data indicate robust stem cell mobilization in MM patients treated with novel agents, with G-CSF and either ID-CY or plerixafor. When compared with plerixafor, ID-CY-containing mobilization was associated with significantly lower average total mobilization costs.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Hematopoietic Stem Cell Mobilization/methods , Multiple Myeloma/therapy , Peripheral Blood Stem Cell Transplantation/methods , Adult , Aged , Benzylamines , Cyclams , Cyclophosphamide/administration & dosage , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Hematopoietic Stem Cell Mobilization/economics , Heterocyclic Compounds/administration & dosage , Humans , Male , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/drug therapy , Multiple Myeloma/surgery , Retrospective Studies
10.
Leuk Lymphoma ; 43(1): 127-32, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11908716

ABSTRACT

Adult T-cell leukemia/lymphoma (ATLL), in its acute stage, is a uniformly fatal disease. ATLL is caused by the human T-cell lymphotropic virus I (HTLV-1), a retrovirus endemic in numerous areas throughout the world including Japan, the Caribbean, Central and South America and certain areas of the United States. Although the progression from HTLV-1 carrier status to ATLL occurs only rarely, ATLL is incurable and thus prevention of HTLV-1 transmission should be a primary goal. With the development of new anti-retroviral and monoclonal therapies, there exist potential cures or at least prolonged remissions for patients diagnosed with ATLL. We present a case of ATLL that, to our knowledge, is only the third reported case in Georgia. In addition, we present a brief review of the literature, including potential new treatment regimens that appear to have promise in the treatment of ATLL.


Subject(s)
Leukemia-Lymphoma, Adult T-Cell/pathology , Leukemia-Lymphoma, Adult T-Cell/transmission , CD4-CD8 Ratio , Epidemiology , Family Health , Female , Georgia , Humans , Immunophenotyping , Leukemia-Lymphoma, Adult T-Cell/diagnosis , Leukemia-Lymphoma, Adult T-Cell/drug therapy , Lymphocytes/immunology , Lymphocytes/pathology , Male , Middle Aged , Spouses
11.
Leuk Lymphoma ; 43(1): 199-201, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11908730

ABSTRACT

Central nervous system (CNS) involvement in early (Rai Stage 0 and Stage 1) chronic lymphocytic leukemia (CLL) is rare, with only five cases reported. We present the sixth reported case, a 77-year-old male with a 4 year history of Stage 0 CLL who presented with sudden onset of diplopia and headache. Workup revealed a leukemic involvement of his CNS and he responded well to treatment with intrathecal (IT) methotrexate. After his third IT treatment, he developed a change in his mental status, consistent with a chemotherapy induced encephalopathy, which was effectively treated with IT hydrocortisone. In addition to the case presentation, we review the previously reported cases in an effort to determine any characteristics common among the Stage 0/1 CLL patients with reported CNS involvement.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Meningeal Neoplasms/pathology , Aged , Brain Diseases/chemically induced , Brain Diseases/drug therapy , Humans , Hydrocortisone/administration & dosage , Injections, Spinal , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemic Infiltration/diagnosis , Leukemic Infiltration/drug therapy , Male , Meningeal Neoplasms/diagnosis , Meningeal Neoplasms/drug therapy , Methotrexate/administration & dosage , Methotrexate/adverse effects , Neoplasm Staging , Treatment Outcome
13.
Med Oncol ; 18(2): 149-51, 2001.
Article in English | MEDLINE | ID: mdl-11778761

ABSTRACT

Tumor lysis syndrome, resulting from the abrupt release of intracellular ions into the blood stream due to sudden tumor cell death, is a serious complication of chemotherapy treatment. This syndrome occurs more frequently in hematologic malignancies and lymphomas. Its incidence in solid tumors is rare, but has a high mortality rate owing to the lack of prophylactic therapy to prevent this complication. We report a case of tumor lysis syndrome accompanied by death in a patient with extensive stage small cell lung cancer who was treated with cisplatin and etoposide, and review the risk factors associated with the syndrome in solid tumor patients who are likely to respond to chemotherapy.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Small Cell/drug therapy , Lung Neoplasms/drug therapy , Tumor Lysis Syndrome/pathology , Carcinoma, Small Cell/complications , Fatal Outcome , Humans , Lung Neoplasms/complications , Male , Middle Aged , Risk Factors , Tumor Lysis Syndrome/etiology
14.
Med Oncol ; 17(4): 287-92, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11114707

ABSTRACT

Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2 (CTCb) followed by stem cell transplantation. Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation. A pretransplant complete hearing study was obtained which consisted of hearing case history, audiometry and tympanometry. In addition, DPOAE (Distortion Product Otoaccoustic Emissions) was done to evaluate measurable changes in the cochlear (outer hair cell) functioning. Pre-transplant, all patients had no clinical evidence of hearing impairment and hearing studies were normal. Eleven patients had hearing studies and a telephone interview posttransplant. One patient was lost to follow-up and two patients died. One of the 11 patients tested had an abnormal post-transplant hearing study but none of them had clinically detectable hearing impairment. In our prospective study of breast cancer patients treated with the CTCb regimen, we did not observe clinically detectable hearing impairment in any of the patients tested.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/drug therapy , Deafness/chemically induced , Hematopoietic Stem Cell Transplantation , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carboplatin/administration & dosage , Carboplatin/adverse effects , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Female , Humans , Middle Aged , Otoacoustic Emissions, Spontaneous/drug effects , Prospective Studies , Thiotepa/administration & dosage , Thiotepa/adverse effects
15.
Bone Marrow Transplant ; 26(8): 925-7, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11081398

ABSTRACT

Autoimmune thrombocytopenia after high-dose chemotherapy and autologous bone marrow/peripheral blood stem cell transplantation occurs infrequently and only six cases meeting the criteria have been reported in the literature. All six of these patients had either acute myelogenous leukemia (AML) or lymphoblastic lymphoma (LBL). Immune thrombocytopenia following autologous transplantation in solid tumors has not been reported. We report the first case of autoimmune thrombocytopenia after high-dose chemotherapy and peripheral blood stem cell transplantation in a patient with breast cancer. A review of the literature has been conducted and treatment options are discussed. In two patients the condition resolved with treatment and in a third patient it improved. Immune-mediated thrombocytopenia in the post-transplant period is one of the causes of a low platelet count. It should be recognized promptly and treated.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Purpura, Thrombocytopenic, Idiopathic/etiology , Breast Neoplasms/therapy , Female , Humans , Middle Aged , Purpura, Thrombocytopenic, Idiopathic/therapy , Transplantation, Autologous
16.
Cancer Invest ; 18(7): 609-13, 2000.
Article in English | MEDLINE | ID: mdl-11036468

ABSTRACT

Advanced-stage cutaneous T-cell lymphoma (CTCL) is generally resistant to standard chemotherapy. Because P-glycoprotein (P-gp) has been detected in other types of resistant solid tumors, leukemias, and lymphomas, we analyzed P-gp expression in CTCL. Twenty-seven patients with CTCL and circulating Sezary cells in the peripheral blood as observed on a peripheral smear treated at the Yale Photopheresis Center between 1987 and 1993 were identified. Twenty-five of these patients had skin biopsies evaluated for expression of P-gp using JSB-1 (Accurate Chemical), MRK-16 (gift of T. Tsuruo), and UIC-2 (gift of E. Metchner). P-gp expression was considered present if immunoreactivity was noted with two of the three antibodies. Eighteen of 25 patients (72%) evaluated exhibited expression. The patients were treated with various combinations of drugs consisting of topical and systemic steroids electron beam therapy, psoralens in combination with UV light A (PUVA), systemic chemotherapy, and photopheresis before testing the tissue for P-gp expression. Treatment with systemic chemotherapy in P-gp-positive patients produced responses in 3 and no responses in 11 patients (4 were lost to follow-up). Seven patients did not express P-gp: One patient responded to treatment, five did not respond, and one patient was lost to follow-up. These results demonstrate that P-gp is frequently expressed in CTCL. P-gp expression in our study was not a useful predictor of drug resistance.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Lymphoma, T-Cell, Cutaneous/drug therapy , Adult , Aged , Aged, 80 and over , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Female , Humans , Lymphoma, T-Cell, Cutaneous/metabolism , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged
17.
Leuk Lymphoma ; 38(3-4): 419-22, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10830750

ABSTRACT

Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent edema that responded a second time to salvage chemotherapy. The second patient died of gram positive sepsis a week after diagnosis. As anasarca is an unusual presenting symptom of non-Hodgkin's lymphoma, we postulated that the malignant cells were secreting a cytokine that resulted in "vascular leakage" of fluid and development of diffuse edema. Several serum cytokine levels were tested. Both patients had elevated TNF-alpha levels, which could have been the cause of the edema; or there might be yet another unidentified mediator that was responsible for the anasarca. We report these two cases to bring to attention the unusual nature of this presentation.


Subject(s)
Edema/etiology , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, T-Cell/complications , Neoplasm Proteins/physiology , Tumor Necrosis Factor-alpha/physiology , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Capillary Leak Syndrome/etiology , Cyclophosphamide/administration & dosage , Cytokines/blood , Doxorubicin/administration & dosage , Fatal Outcome , Female , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/metabolism , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/metabolism , Male , Prednisone/administration & dosage , Serum Albumin/deficiency , Vincristine/administration & dosage
18.
Am Surg ; 66(3): 250-4; discussion 255, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10759194

ABSTRACT

Despite increasing public awareness and widespread availability of mammography, many patients will present with locally advanced breast cancers. The role of surgery remains controversial. Between 1993 and 1998, 47 of 393 (11.9%) breast cancer patients presented with T4 (inflammatory or locally advanced) carcinoma. We reviewed multimodality management, clinical response to neoadjuvant therapy, perioperative course and complications, and local control. Forty-six women and one man were diagnosed with clinical T4 breast cancer. There were 24 white and 23 African-American patients. Mean age at presentation was 54.5 (range, 31-88) years. Twenty-three patients had clinical metastases to axillary nodes, and five had distant metastases at the time of diagnosis. For these women, intent was for personal hygiene and control of pain. Neoadjuvant chemotherapy was given for 34 of 47 (72%) with 25 of 34 (73.5%) having partial or complete clinical response. There was no response or progression of disease in 9 of 34(26.5%). Forty-six patients underwent radical or modified radical mastectomy, whereas a single patient underwent breast conservation treatment. Twelve required tissue transfer for wound coverage. Although eight developed minor wound complications (cellulitis/flap separation), there were no major wound complications. Pathologically negative margins were achieved in all but one patient. To date, five women have developed local recurrence in either the chest wall (three) or axilla (two). Average time to local recurrence was 7.8 months. There is no evidence of local failure in the remaining 87 per cent. Locally advanced breast cancer is a common occurrence in certain populations. Multimodality management remains the standard of care. Surgical resection may allow for successful local control and, in certain situations, long-term cure.


Subject(s)
Breast Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Breast Neoplasms, Male/surgery , Disease-Free Survival , Female , Humans , Male , Mastectomy , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Neoplasm Staging
19.
J Hematother Stem Cell Res ; 9(6): 849-54, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11177596

ABSTRACT

Twenty-nine patients received high-dose chemotherapy and autologous stem cell transplantation from June 1997 to December 1998. The number of CD34+ cells reinfused was 2.4 x 10(6) to 69.0 x 10(6)/kg. Twelve patients developed a fever in the immediate postengraftment period. One patient had a documented infection that could account for the fever; a second patient had a rash and biopsy proven acute graft-versus-host disease (GvHD) that responded to steroids. In the other 10 patients (30%) there was no identifiable cause of the fever. One of these patients received 4.2 x 10(6) CD34+ cells/kg. The other nine received 22.0 x 10(6) to 69.0 x 10(6) CD34+ cells/kg. In our series of 29 patients, 9 of the 11 (82%) patients who received > 20 x 10(6) CD34+ cells/kg developed fever in the postengraftment period. There was a significant association between the number of CD34+ cells (<20 vs. >20 x 10(6)) and occurrence of fever (odds ratio = 76.5; p = 0.00005). Even though they engrafted promptly (7 to 9 days), the fever required evaluation for infection, blood cultures, antibiotic treatment, and observation. This required additional hospitalization of 1 to 7 days. These data suggest that a high number of CD34+ cells is frequently associated with post-engraftment fever and prolongation of the hospital stay. Should there be an upper limit in the number of reinfused CD34+ cells is a question that has to be addressed and possibly studied.


Subject(s)
Antigens, CD34/blood , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Fever/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Adult , Age Factors , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/complications , Breast Neoplasms/therapy , Female , Graft vs Host Disease/etiology , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cells/immunology , Humans , Middle Aged , Neoplasms/complications , Neoplasms/therapy , Odds Ratio , Retrospective Studies , Sex Factors , Transplantation, Autologous
20.
Bone Marrow Transplant ; 23(11): 1095-100, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10382947

ABSTRACT

This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m2 twice a day x six doses on days -7, -6, and -5; cyclophosphamide 1800 mg/m2 on days -4 and -3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days -4, -3, -2, and -1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69% (58-82) and at 5 years was 54% (42-69) with the numbers in parentheses representing the 95% confidence interval of the Kaplan-Meier estimate. After a median follow-up of 28 months, 31 of 58 (53%) patients are alive without evidence of disease. Only four of the 58 patients (7%) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7% with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study.


Subject(s)
Bone Marrow Transplantation , Cyclophosphamide/therapeutic use , Cytarabine/therapeutic use , Leukemia/therapy , Transplantation Conditioning , Whole-Body Irradiation , Adolescent , Adult , Child , Child, Preschool , Cyclophosphamide/adverse effects , Cytarabine/adverse effects , Female , Graft vs Host Disease/etiology , Hepatic Veno-Occlusive Disease/etiology , Humans , Leukemia/mortality , Male , Middle Aged , Prospective Studies , Recurrence , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...